Pharsight

Drug name - Alecensa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(8 years from now)

CN102459172A HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

CN102459172B HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

IN201200152P4 HOFFMANN-LA ROCHE Tetracyclic Compound
Jun, 2030

(7 years from now)

IN294424B HOFFMANN-LA ROCHE Tetracyclic Compound
Jun, 2030

(7 years from now)

EP3345903A1 HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

EP3345903B1 HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

EP2975024A1 HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

EP2975024B1 HOFFMANN-LA ROCHE Tetracyclic Compounds
Jun, 2030

(7 years from now)

EP2441753A4 HOFFMANN-LA ROCHE Tetracyclic Compound
Jun, 2030

(7 years from now)

EP2441753B1 HOFFMANN-LA ROCHE Tetracyclic Compound
Jun, 2030

(7 years from now)

EP2441753A1 HOFFMANN-LA ROCHE Tetracyclic Compound
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound Jun, 2030

(7 years from now)

US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound Mar, 2032

(9 years from now)

US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose Apr, 2035

(12 years from now)

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.